Yalda Hekmatshoar

Istanbul, 34147, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Targeting Integrin α2 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells.

Targeting Integrin α2 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells.

Journal: Biomolecules

Published: July 22, 2025

Multifaceted Therapeutic Potential of Plant-Derived Exosomes: Immunomodulation, Anticancer, Anti-Aging, Anti-Melanogenesis, Detoxification, and Drug Delivery.

Multifaceted Therapeutic Potential of Plant-Derived Exosomes: Immunomodulation, Anticancer, Anti-Aging, Anti-Melanogenesis, Detoxification, and Drug Delivery.

Journal: Biomolecules

Published: February 06, 2025

Combating chronic kidney disease-associated cachexia: A literature review of recent therapeutic approaches.

Combating chronic kidney disease-associated cachexia: A literature review of recent therapeutic approaches.

Journal: BMC nephrology

Published: November 23, 2024

Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia.

Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: April 11, 2024

Methylsulfonylmethane induces caspase-dependent apoptosis in acute myeloid leukemia cell lines.

Methylsulfonylmethane induces caspase-dependent apoptosis in acute myeloid leukemia cell lines.

Journal: Fundamental & clinical pharmacology

Published: March 26, 2024

Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics Study.

Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics Study.

Journal: Nucleosides, nucleotides & nucleic acids

Published: December 20, 2023

Nilotinib exhibits less toxicity than imatinib and influences the immune state by modulating iNOS, p-p38 and p-JNK in LPS/IFN gamma-activated macrophages.

Nilotinib exhibits less toxicity than imatinib and influences the immune state by modulating iNOS, p-p38 and p-JNK in LPS/IFN gamma-activated macrophages.

Journal: Toxicology in vitro : an international journal published in association with BIBRA

Published: July 31, 2023

Some 2-[4-(1H-benzimidazol-1-yl) phenyl]-1H-benzimidazole derivatives overcome imatinib resistance by induction of apoptosis and reduction of P-glycoprotein activity.

Some 2-[4-(1H-benzimidazol-1-yl) phenyl]-1H-benzimidazole derivatives overcome imatinib resistance by induction of apoptosis and reduction of P-glycoprotein activity.

Journal: Chemical biology & drug design

Published: April 30, 2023

Evidence for Health-Promoting Properties of Lepidium sativum L.: An Updated Comprehensive Review.

Evidence for Health-Promoting Properties of Lepidium sativum L.: An Updated Comprehensive Review.

Journal: Turkish journal of pharmaceutical sciences

Published: December 22, 2022

Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line.

Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line.

Journal: Advances in medical sciences

Published: November 29, 2022

Downregulation of Stearoyl-CoA Desaturase 1 (SCD-1) Promotes Resistance to Imatinib in Chronic Myeloid Leukemia.

Downregulation of Stearoyl-CoA Desaturase 1 (SCD-1) Promotes Resistance to Imatinib in Chronic Myeloid Leukemia.

Journal: Mediterranean journal of hematology and infectious diseases

Published: October 07, 2022

Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.

Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.

Journal: Leukemia research

Published: January 18, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026